InvestorsHub Logo
Followers 3
Posts 70
Boards Moderated 0
Alias Born 02/06/2016

Re: None

Sunday, 02/21/2016 9:28:00 AM

Sunday, February 21, 2016 9:28:00 AM

Post# of 3683
ATHX MAY in negotiations FIRST with Japan for ACCELERATED APPROVAL.
1)Based on the 12 month follow up data (Hess et al 2016). 29% EXCELLENT EFFICACY which is ,both a STAT. SIGNIFICANT( p=0.02)and a CLINICALLY significant IMPROVEMENT over the current STANDARD of CARE--.. EXTENSION of therapy window from 3 hrs to 36 hrs.
.2) IMPACT on potentially 15 million patients WORLD WIDE.

3)This STAT.SIG (p=0.02), HIGH clinical a) EFFICACY and b) IMPACT was documented within a GOLD standard research methodology---RANDOMIZED DOUBLE BLIND PLACEBO controlled study.